Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00108836 | Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder | PHASE2 | COMPLETED | 400 | — | — | Mar 1, 2005 | May 1, 2006 | May 20, 2010 | 23 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| XBD173 | DRUG | - |
Inclusion Criteria: * Current doctor's diagnosis of generalized anxiety disorder * In need of psychiatric treatment * Willingness to complete all aspects of the study Exclusion Criteria: * Current doctor's diagnosis of major depression * History of schizophrenia or schizoaffective disorders * Dru...